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Abstract
Background: This study aimed at assessing the effectiveness and safety of repeated administrations of allogeneic
bone marrow-derived mesenchymal stem cells (BM-MSCs) primed with tumor necrosis factor (TNF)-α and interferon-γ
in an equine model of chemically-induced osteoarthritis. Arthritis was induced in both radio-carpal (RC)-joints by
amphotericin-B in 18 ponies, divided into three groups depending on the treatment injected: MSC-naïve (n = 7), MSC-
primed (n = 7) and control (n = 4). The study consisted of two phases and used one RC-joint of each animal in each
phase, with four months time-lapse, in order to assess two end-points. Clinical, synovial, radiological and ultrasonographic
follow-up was performed. At six months, animals were euthanized and both carpi were assessed by magnetic resonance
imaging (MRI), gross anatomy, histopathology, histochemistry and gene expression.
Results: Clinical and synovial inflammatory signs were quicker reduced in MSC-treated groups and repeated allogeneic
administration did not produce adverse reactions, but MSC-primed group showed slight and transient local inflammation
after second injection. Radiology and MRI did not show significant differences between treated and control groups,
whereas ultrasonography suggested reduced synovial effusion in MSC-treated groups. Both MSC-treated groups showed
enhanced cartilage gross appearance at two compared to six months (MSC-naïve, p < 0.05). Cartilage histopathology did
not reveal differences but histochemistry suggested delayed progression of proteoglycan loss in MSC-treated groups.
Synovium histopathology indicated decreased inflammation (p < 0.01) in MSC-primed and MSC-naïve at two and six
months, respectively. At two months, cartilage from MSC-primed group significantly (p < 0.05) upregulated collagen type
II (COL2A1) and transforming growth factor (TGF)-β1 and downregulated cyclooxygenase-2 and interleukin (IL)-1β. At six
months, MSC-treatments significantly downregulated TNFα (p < 0.05), plus MSC-primed upregulated (p < 0.05) COL2A1,
aggrecan, cartilage oligomeric protein, tissue inhibitor of metalloproteinases-2 and TGF-β1. In synovium, both MSC-
treatments decreased (p< 0.01) matrix metalloproteinase-13 expression at two months and MSC-primed also
downregulated TNFα (p < 0.05) and IL-1β (p < 0.01).
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Conclusions: Both MSC-treatments provided beneficial effects, mostly observed at short-term. Despite no huge
differences between MSC-treatments, the findings suggested enhanced anti-inflammatory and regulatory potential of
MSC-primed. While further research is needed to better understand these effects and clarify immunogenicity implications,
these findings contribute to enlarge the knowledge about MSC therapeutics and how they could be influenced.
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Background
The lack of effective treatments for joint pathologies
such as osteoarthritis (OA) has risen interest in therapies
based on mesenchymal stem cells (MSCs) [1]. Provided
that their engraftment in the cartilage appears to be low
[2, 3], MSC benefit is being mainly attributed to their
paracrine mechanisms including trophic and immuno-
modulatory properties. Therefore, it has been a shift to-
wards using MSCs to regulate joint inflammation rather
than to replace damaged cartilage [4].
Since the main effect of MSCs in OA appears to be re-
lated to their immunomodulatory and anti-inflammatory
properties [5], the choice of the lesion model to study these
abilities is an important aspect. Enhanced therapeutic
benefit of MSCs has been shown in vitro and in vivo when
a remarkable level of proinflammatory mediators is present
[6, 7], so highly inflammatory OA models could be suitable
for studying the regulatory role of MSCs [8]. Conditions
producing acute joint inflammation can lead to a pro-
longed inflammatory situation and subsequent degradation
of the articular cartilage, which eventually produces de-
generative changes in the joint [9, 10]. Chemically
induced-OA models are used to mimic this process in dif-
ferent species, including the horse, since they are charac-
terized by a significant initial inflammatory component.
Amphotericin-B intra-articular (IA) injection has been
used to induce acute arthritis in the horse which can lead
to degenerative changes in the cartilage [11–13]. The in-
flammation generated includes elevated matrix metallopro-
teinases (MMP) activity during several weeks, to an extent
capable of promoting degradation of the extracellular
matrix (ECM) of the articular cartilage [12]. Furthermore,
MMP dysregulation plays a key role in OA progression
since the cartilage ECM disruption is mainly perpetrated
by enzymatic degradation [14]. Therefore, inflammation
generated in this model eventually results in erosive lesions
of the articular cartilage related to OA [11, 12].
Provided that inflammation plays a key role in OA
pathophysiology by promoting cartilage breakdown, an
optimal therapeutic approach should try to both limit in-
flammation and stimulate regeneration of articular struc-
tures [15]. Regulatory abilities elicited by MSCs in the
inflammatory and catabolic environment of the diseased
joint seem to be a multifactorial process, involving both
direct cell-to-cell contact and paracrine signaling through
different molecules governing the regulation of immune
and inflammatory cells [3]. Mesenchymal stem cells may
elicit immune regulatory effects in basal conditions, but
the induction of their full immunomodulatory function re-
quires activation by inflammatory signals [16, 17]. This
fact is closely related with the aforementioned suitability
of inflammatory OA models. In fact, improved MSC out-
come has been shown in mice when using models charac-
terized by high inflammatory component [6] rather than
when using destabilization models [18]. Similarly, en-
hanced outcome of autologous MSCs has been observed
in the equine amphotericin-B model [11] compared to the
post-traumatic OA model [19], which has been proposed
to be due to higher severity of the amphotericin-B model
[20]. However, inflammatory environment encountered by
MSCs in the site of injury may not be sufficient for full
MSC activation [21], so in vitro MSC priming with
pro-inflammatory molecules prior to their administration
could be a suitable approach to enhance their therapeutic
benefit [16]. Actually, tumor necrosis factor (TNF)α-prim-
ing increased in vivo MSC benefit in Achilles tendon in-
jury rat model [22] and interferon (IFN)γ-stimulated
equine MSCs showed enhanced effects in a murine OA
model, supporting the potential of this strategy [8]. Fur-
thermore, the enhanced immune suppressive properties of
primed MSCs might help the allogeneic ones to evade the
receptor immune system [23]. On the other hand, MSC
inflammatory priming may also induce or increase the ex-
pression of major histocompatibility complex (MHC) mol-
ecules [24], with potential implications for their allogeneic
use. Nevertheless, allogeneic MSCs primed with IFNγ dis-
played therapeutic benefit in different pathology models
[23], so further investigation is needed to clarify both ef-
fectiveness and safety of primed allogeneic MSCs because
of their potential benefits.
Allogeneic therapy, among other advantages, enables
earlier MSC administration [25]. Even though the optimal
moment for MSC treatment has yet to be elucidated, en-
hanced outcome has been reported in an equine model
when MSCs were earlier administered after amphotericin-B
arthritis induction. In that study, improvement begun at
two months but was not consistently maintained at six
months [11]. Thus, Mokbel and colleagues proposed that
enhanced benefit could have been reached by using re-
peated MSC administrations [11], similarly to that reported
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in a porcine model of meniscal injury [26]. Repeated IA in-
jections of allogeneic MSCs pooled from several donors are
clinically safe in the equine healthy joint [27], as well as sin-
gle IA administration of allogeneic MSCs into the equine
pathologic joints [28, 29]. However, repeated allogeneic
MSC administration in equine pathologic joints has not yet
been reported, neither the effects of inflammatory primed
MSCs in the horse.
Equine bone marrow derived MSCs (BM-MSCs) primed
with 5 ng/ml of TNFα and IFNγ during 12 h induced their
immunomodulatory profile while preserving cell viability
and differentiation ability, with moderate increase of
MHC-II expression [17], so these stimulatory conditions
could be suitable to assess the effects of primed cells in vivo.
Therefore, the aim of this study was to assess the use of re-
peated injections of allogeneic donor-pooled BM-MSCs, na-
ïves (unstimulated) or primed with TNFα and IFNγ, in an
equine model of chemically induced-OA to evaluate the
safety and effectiveness of this strategy. We hypothesized
that the induction of the immune regulatory profile of
equine BM-MSCs would have a positive impact on their
therapeutic effects in an equine joint pathology model.
Methods
Study design
The study design consisted of two phases and involved
18 animals divided into three groups (control, n = 4;
MSC-naïve, n = 7; MSC-primed, n = 7), whose 36
radio-carpal (RC)-joints were used: 18 RC-joints (one of
each animal) for phase 1 and the contralateral 18
RC-joints in the phase 2. Smaller size of the control group
was selected to enlarge treatment groups, based on previ-
ously reported reliability of this design [30]. In the phase
1, acute arthritis was induced in one RC-joint of each ani-
mal (n = 18) through IA injection of amphotericin-B.
Radio-carpal joints received two injections (Weeks 2 and
5 post-lesion induction) of corresponding substance:
allogeneic pooled BM-MSCs unstimulated (MSC-naïve
group, n = 7 RC-joints), or primed by TNFα and IFNγ
(MSC-primed group, n = 7 RC-joints), or Lactate’s Ringer
Solution (LRS) (control group, n = 4 RC-joints). Clinical,
synovial, ultrasonographic and radiologic assessments
were performed weekly until two months post-induction.
The phase 2 started at four months, after additional two
months interval. Lesions were induced in the contralateral
RC-joint of each animal and they were subjected to the
same corresponding procedure including repeated injec-
tion of the same substances and follow-up until two
months. Then, at six months, animals were euthanized
and magnetic resonance imaging (MRI), gross anatomy,
histopathology, histochemistry and gene expression of car-
tilage and synovium were assessed. Schematic representa-
tion of the study design is provided in Additional file 1.
This two-phases study design aimed at evaluating two
different end-points (two months for phase 2 RC-joints
and six months for phase 1 RC-joints) without duplicat-
ing the number of animals, since the migration of IA
injected MSCs from one joint to another appears to be
unlikely [31, 32] and both joints of each animal are often
used in studies involving large animal models which in-
duce the lesions either at the same time [11, 33–35] or
separately at different times [36].
Animals
Eighteen animals (Shetland ponies, geldings, 3–7 years,
100–165 kg) were selected based on homogeneous char-
acteristics (breed, sex, age, weight) and included in the
study after ensuring good health status and lack of
RC-joint abnormalities. Animals were acquired from a
local equine marketplace. All animals were determined to
be in good health based on clinical and hematological
exams and absence of RC-joint pathology was assessed by
clinical (static and dynamic exams, including range of mo-
tion and flexion test), synovial and radiological exams.
The animals were randomly divided into three groups ar-
ranged as described above. Animals in the control group
served as donors of allogeneic BM-MSCs. All procedures
were carried out under Project License (PI 31/11) ap-
proved by the Ethic Committee for Animal Experiments
from the University of Zaragoza. The care and use of ani-
mals were performed in accordance with the Spanish Pol-
icy for Animal Protection RD53/2013, which meets the
European Union Directive 2010/63 on the protection of
animals used for scientific purposes.
Equine BM-MSCs isolation, characterization and culture
Animals from control group (n = 4) were sedated with
0.04 mg/kg IV romifidine (Sedivet, Boehringer-Ingelheim)
and 0.02mg/kg IV butorphanol (Torbugesic, Pfizer) and
20–30 mL of bone marrow were collected from sternum
in heparinized syringes with a Jamshidi needle. Procedures
for MSC isolation, characterization and culture were per-
formed as previously described [17]. Briefly, nucleated cells
were harvested by density gradient centrifugation (Lym-
phoprep, Atom) and cultured in basal medium (low glu-
cose Dulbecco’s Modified Eagle’s Medium [DMEM] with
10% fetal bovine serum [FBS], 2 mM L-glutamine, 0.1 mg/
mL streptomycin and 100 U/mL penicillin [all from
Sigma-Aldrich]) at 37 °C, 5% CO2. At passage 3, cells were
characterized by flow cytometry and real time quantitative
polymerase chain reaction (RT-qPCR) for surface markers
expression and by tri-lineage differentiation potential ac-
cording to methodology previously described [37]. Details
about characterization of equine BM-MSCs can be found
in Additional file 2. Subsequently, BM-MSCs were frozen
in medium FBS with 10% dimethyl-sulfoxide (DMSO) (Sig-
ma-Aldrich) (− 80 °C).
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Acute arthritis induction
Animals were sedated as described above and 25 mg of
amphotericin-B (Sigma-Aldrich) were IA injected through
aseptic arthrocentesis in one randomly assigned RC-joint
(phase 1) [11, 38]. The same procedure was repeated four
months later in contralateral RC-joints (phase 2). Animals
did not receive any anti-inflammatory drug that could
have interfered with the development of the arthritis. An-
algesia was provided as previously described [38]: 0.1 mg/
kg IV butorphanol were administered every 8 h during
3 days and additional dose was provided if animals pre-
sented heart rate (HR) > 60, respiratory rate (RR) > 48 or
rectal temperature > 38.8 °C within the 8 h interval. If in-
sufficient, perineural block of the median, radial and ulnar
nerves would be performed with bupivacaine 0.5%
(Braun). Animals were located in boxes during 15 days
post-induction and subsequently placed in ample pad-
docks allowing free movement.
Preparation of MSC-naïve, MSC-primed and control
injections
Cryopreserved BM-MSCs (passage 3) were thawed seven
days before each administration and cultured in basal
medium described above. Medium of BM-MSCs destined
to the MSC-primed group was replaced by medium con-
taining 5 ng/mL of TNFα and IFNγ (R&D Systems) at 12 h
before the administration [6]. BM-MSCs from the four do-
nors were proportionally mixed and washed three times
with PBS (Gibco) and three times with LRS (Braun).
Subsequently, 10·106 (containing approximately 2.5·106
cells/donor) of naïve or primed BM-MSCs were sus-
pended in 2 mL LRS and IA administered to corre-
sponding animals. Ponies from control group received
the same volume of LRS. All injections were performed
blindly for the substance administered by wrapping the
syringe with aluminum foil.
The effects of the cytokine priming on equine
BM-MSC immunomodulatory and immunogenic pro-
files, as well as on their viability and differentiation po-
tential, were already described by our group, as those
were the same cells than the used in the present study.
Briefly, MSC viability was well preserved after proin-
flammatory priming and under culture with inflamma-
tory synovial fluid (SF) [17, 39], as shown by appropriate
proliferation, absence of changes in the BAX/BCL-2 ra-
tio and lack of DNA damage. Furthermore, immuno-
modulatory profile was upregulated in MSC-primed
compared to MSC-naïve. On the other hand, the expres-
sion of MHC-II increased in MSC-primed, but MHC-I
expression was not induced [17].
Clinical assessment
General health status, HR, RR and rectal temperature
were recorded every 8 h throughout 15 days post-lesion
induction. Lameness scores were assigned [40] and joint
inflammation was monitored by determining the carpal
circumference and the local heat with a non-contact infra-
red laser thermometer (Thermolab) [27]. This complete
clinical exam was performed before inducing the lesion
(Time 0) and afterwards weekly until the Week 6, at two
months (phase 1 and 2 carpi, n = 36), and at four and six
months (only phase 1 carpi, n = 18). Additionally, clinical
exam was performed 24 h after every injection.
Synovial fluid assessment
Synovial fluid (0.5-1 mL) was collected in EDTA at Time
0 and afterwards weekly from Weeks 2 to 6, at two
months (phase 1 and 2 carpi, n = 36) and at 6 months
(only phase 1 carpi, n = 18). Total protein (TP) was de-
termined by refractometry (Spectrum Technologies),
total white cells count (tWCC) was recorded with a
hemocytometer chamber and Diff-Quick (PreAnalityX)
stained cytological preparations were examined to report
the percentage of neutrophils, lymphocytes and macro-
phages (differential WCC, dWCC) [27].
Haptoglobin determination in serum and SF
At the same time-points as SF collection, 5 mL of blood
were harvested (n = 18 animals). Both SF and blood were
centrifuged at 3000 g/15 min for obtaining SF supernatant
and serum, which were stored at − 80 °C. Haptoglobin
was determined following the methodology described
[38]. Briefly, single radial immunodiffusion was carried
out in 1% agarose gel containing rabbit polyclonal antisera
anti-haptoglobin. Concentrations were obtained by ex-
trapolation from a standard curve of known concentra-
tions of commercial equine haptoglobin (Mybiosources).
Ultrasonography and radiology
Ultrasonography was performed at the same time-points
as SF collection. Radiographs were taken on Time 0,
Week 2, and at two (phase 1 and 2 carpi, n = 36), four
and six months (only phase 1 carpi, n = 18). Ultrasound
images were taken using a Zonare Z-One machine using
a linear transducer (5–14 MHz, Zonare, Inc.) that was
transversally placed on the dorsal aspect of the carpus,
slightly lateral, at the level of the RC-joint to assess soft
tissues surrounding the joint, joint capsule, joint effusion
and the articular surface of radiocarpal and intermediate
carpal bones that was ultrasonographically accessible
[41]. Radiographs were taken using an X-ray generator
Orange 8016HF (M&I Globaltech) and 24 × 30 cm plates
FCR FujiIPCassette-CC using 60 kv, 5 mAs and 60 cm
focal distance, and processed using a FCR-Prima
CR-IR391RU computerized radiology system (all from
Fujifilm). Four of the authors (AV, JA, MP, FJV) blindly
assessed the radiographs and assigned a score to each
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one by consensus agreement following an ordinal scale
(Additional file 3.A, adapted from [11]).
Magnetic resonance imaging
Six months since the start of the study, ponies were se-
dated and subsequently euthanized with 200 mg/kg IV
sodium pentobarbital (Euthasol, Esteve). All the carpi
(phase 1, n = 18; phase 2, n = 18) were subjected to MRI
by using an AIRIS II-1 0.3 T MRI unit (Hitachi) and a
knee coil. T2* gradient echo and fat suppression se-
quences were used for coronal and sagittal planes images
acquisition (Additional file 4). Two of the authors (JA,
MR) blindly assessed complete MRI sequences and
scored each RC-joint by consensus agreement. For each
RC-joint, evaluators assigned a value from 0 (normal) to
4 (severely abnormal) for the parameters osteophyte for-
mation, synovial effusion, osseous edema and subchon-
dral bone damage (adapted from [34]).
Gross anatomy and histopathology
Immediately after MRI, gross anatomy was evaluated by
consensus agreement between four blinded evaluators
(AV, JA, MP, FJV) by using an ordinal scale adapted to
assess degenerative changes in the articular surface. Im-
mediately after, synovium and cartilage samples were
collected and split for histopathology and gene expres-
sion analyses. Synovium was harvested from the dorsal
aspect of each joint. Slices of full-thickness cartilage
were collected from the medial aspect of the radiocarpal
bone and the distal radius and from areas of maximal in-
jury. Samples were fixed in 10% formalin, embedded in
paraffin, cut into 5 μm sections and stained with
haematoxylin-eosin (H&E). Cartilage histochemistry was
performed in additional sections stained by Safranin
O-Fast Green (SOFG) to assess proteoglycan content
by stain uptake [42, 43]. Three sections from each sam-
ple for both H&E and SOFG staining were assessed by
one blinded external evaluator, who assigned scores
following an ordinal scale (scales adapted from [42],
Additional file 3.B). Parameters included in the scales
were analyzed both separately and summed up to pro-
vide overall score. Histochemistry assessment by SOFG
was separately evaluated.
Gene expression
Samples destined to gene expression analysis were fro-
zen and RNA was isolated with the Trizol (Qiagen)/
Chloroform/Isopropanol method. The kit DNAseTurbo
(Ambion) was used to remove genomic DNA and RNA
quantity and purity were measured with the NanoDrop
ND-1000 Spectrophotometer (Thermofisher). The Mean
± S.E.M of the ratio 260/280 was 1.935 ± 0.071 for cartil-
age and 1.945 ± 0.096 for synovium, reflecting appropri-
ate RNA purity [44]. Subsequently, 1 μg of RNA was
retrotranscripted into cDNA with the SuperScript-II Sys-
tem (Life Technologies), following the manufacturers’ in-
structions. The expression of genes related to ECM
production, destruction/remodeling and joint inflamma-
tion were analyzed by RT-qPCR using the Fast SYBR
Green Master Mix and the StepOne RT-qPCR System de-
vice (all from Applied Biosystems). Full list of genes and
corresponding primers can be found in Additional file 5.
The gene expression levels were determined by the ΔΔCt
method using a normalization factor calculated as the geo-
metric mean of two housekeeping genes (GAPDH and
B2M). Methodology for gene expression analyses was per-
formed as previously reported [45].
Statistical analysis
Statistical analysis was performed with the SPSS 15.0
(SPSS, Inc.). Normality was tested with the Shapiro-Wilk
test. The aim of using both carpi of each animal for a
two-phase design was to compare them at different
end-points but not along the study, since the procedure
was the same in both phases up to two months. Therefore,
the data collected along the study from both phase 1 and
phase 2 carpi were added at each time-point until two
months of evolution. Thus, for clinical, synovial and radio-
logical parameters, the number of RC-joints assessed were
n = 36 until two months (8 RC-joints control, 14 RC-joints
MSC-naïve, 14 RC-joints MSC-primed), and n = 18 from
two to six months (4 RC-joints control, 7 RC-joints
MSC-naïve, 7 RC-joints MSC-primed). For clinical and syn-
ovial parameters, values at each time-point were compared
to those at the moment of the MSC-naïve, MSC-primed or
control injection (Week 2 or 5) with the Wilcoxon test to
study the evolution within each group. Additionally, the
percentages of change at each time-point compared to the
Time 0 were calculated in each group and compared be-
tween groups by the Kruskall-Wallis test followed by
Dunn’s posthoc test. For radiology scores, the same test
was used to assess differences between groups at each
time-point and differences between time-points within each
group were studied by the Friedman test. For MRI, gross
anatomy, histopathology, histochemistry and gene expres-
sion analyses, the results were first compared between
groups at each end-point by Kruskall-Wallis test followed
by Dunn’s posthoc analysis, and subsequently between both
end-points within each group with the Wilcoxon test. Sig-
nificance was set at p < 0.05 for all analysis.
Results
Clinical follow-up
No statistically significant differences were found between
groups at baseline (Time 0, pre-lesion) for clinical param-
eters. All horses developed lameness with marked joint ef-
fusion and local heat within 6 h following amphotericin-B
injection. Signs of joint inflammation peaked at 24-48 h
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and were thereafter progressively decreasing throughout
the study. Despite the transient overload of phase 1 fore-
limbs due to the arthritis induction in the phase 2, clinical
worsening of the phase 1 carpi (i.e. increased lameness or
inflammatory signs) was not detected.
Lameness and local heat did not show significant dif-
ferences between groups but suggested faster decrease
in both MSC-treated groups (Fig. 1a and b). After first
treatment or control injection, carpal perimeter was sig-
nificantly reduced (p < 0.01) in both MSC-treated groups
sooner than in control (Fig. 1c). In addition, comparison
between groups within each time-point was performed
by using the percentage of change of the carpal perim-
eter over Time 0 (pre-lesion). MSC-primed group pre-
sented significantly lower percentage of change (i.e. less
increase in the carpal perimeter) compared to control or
to both control and MSC-naïve groups. This was ob-
served at all time-points after both injections (p < 0.05),
except at 24 h after both first (Week 2) and second
(Week 5) injection (Additional file 6).
Second injection of allogeneic cells led to an increase
in carpal heat (non-significant) and perimeter (p < 0.01)
in MSC-primed group within next 24 h, but not in the
MSC-naïve group. This effect was transient, not accom-
panied by increased lameness or signs of pain, and spon-
taneously resolved by one week later (Fig. 1b-c). Only
one animal in the MSC-primed group developed marked
effusion with signs of pain within few hours after the
second injection in the phase 2, but the reaction was
self-limiting and resolved with no anti-inflammatory
medication (analgesia was provided as described above).
Synovial fluid follow-up
No statistically significant differences were found be-
tween groups at baseline (Time 0, pre-lesion) for syn-
ovial parameters. The highest values for the synovial
parameters assessed were found at Week 2 after the
arthritis induction, just before the first injection of
MSC-naïve, MSC-primed or control substance. Signifi-
cant differences were not found between groups at each
time-point for synovial parameters, but MSC-treated
groups provided quicker normalization: one week after
the first treatment or control injection (Week 3), TP was
significantly reduced only in the MSC-primed group and
one week later (Week 4) also by the MSC-naïve group,
but not in the control group until Week 5. At the end of
the study (six months), only MSC-primed group showed
significantly reduced TP values (p < 0.05) compared to
the moment of the second injection (Fig. 2a).
Similarly, haptoglobin was reduced in SF one week
after first injection (Week 3) in both MSC-treated
groups (p < 0.01) but not in the control (p < 0.05) until
the next week (Week 4). Synovial haptoglobin was sig-
nificantly reduced after second injection of MSC-naïve
Fig. 1 Results from clinical follow-up including lameness score, carpal heat and carpal perimeter. The two-phase study design aimed to perform
paired comparison between two and six months’ end-points but not along the study because both phases 1 and phase 2 carpi underwent the
same procedure. Thus, data collected from both phase 1 and phase 2 carpi was used for analyses until two months. Therefore, number of radio-
carpal (RC)-joints assessed for clinical parameters were n = 36 until two months (8 RC-joints control, 14 RC-joints MSC-naïve, 14 RC-joints MSC-
primed), and n = 18 from two to six months (4 RC-joints control, 7 RC-joints MSC-naïve, 7 RC-joints MSC-primed). Light grey lines and asterisks
correspond to control group, dark grey lines and asterisks to MSC-naïve group and black lines and asterisks to MSC-primed group. Evolution of
each parameter is shown as Mean ± SEM values for each group at each time-point. Significant differences are shown between time-points within
each group: time-points from Time 0 (pre-lesion) to Week 5 (just before second injection) were compared to the time of the first injection (Week
2). Subsequent time-points were compared to second injection (Week 5). a Lameness score (0–5) along the study. b Carpal heat along the study
is shown as the difference between the injected carpus and the contralateral one (injected – contralateral) at each time-point (°C). For the phase
2, it was checked that local temperature had returned to basal values in phase 1 carpi and that there were no differences between opposite
carpi. c Carpal perimeter along the study is shown in centimeters. Note significant reduction of carpal perimeter in groups MSC-naïve and MSC-
primed on Week 3 (one week after first injection) but not in control group until Week 5. Also note the significant increase in carpal perimeter
24 h after second injection only in MSC-primed group, which is subsequently normalized (* = p < 0.05, ** = p < 0.01, *** = p < 0.001)
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(p < 0.001) and MSC-primed (p < 0.01) at two months
and only MSC-primed group showed significant hapto-
globin reduction also in serum (p < 0.05) at two and at
six months (Fig. 2b) (at the beginning of the phase
2 [four months], values of serum haptoglobin were
returned to basal values in the three groups).
Total WCC peaked at Week 3 in control group, whereas
at this time-point tWCC did not increase over Week 2 (first
treatment injection) in the MSC-treated groups. However,
tWCC increased in both control and MSC-primed groups
(p < 0.05) one week after the second injection (Week 6),
but the values were significantly reduced by the end of the
study only in the MSC-primed group (p < 0.05) (Fig. 2c).
Percentage of neutrophils was significantly reduced only by
MSC-treated groups by one week after both first (Week 3,
p < 0.001) and second injections (Week 6, p < 0.05 for
MSC-naïve; p < 0.01 for MSC-primed) (Fig. 2d). Neither
lymphocytes nor macrophages showed significant changes
in their SF counts (data not shown).
Imaging assessment
Radiology showed similar progression in the three groups
with significantly higher scores at all assessed time-points
compared to Time 0 (pre-lesion), but without significant
differences neither between subsequent time-points within
each group, nor between groups at any time-point
(Table 1, Fig. 3a). Ultrasonography showed decreased joint
effusion and capsulitis one week after first injection of
both MSC-naïve and MSC-primed treatments (Fig. 3b).
Slight irregularities in the articular surfaces began to be
detected by two months in the three groups and pro-
gressed along the study with final outcome similar be-
tween groups. In MRI, it was noticed lower synovial
effusion in RC-joints where MSC-naïve were injected
Fig. 2 Synovial fluid (SF) assessment included total protein, haptoglobin, and total and differential white cells counts. The two-phase study design
aimed to perform paired comparison between two and six months’ end-points but not along the study because both phase 1 and phase 2 carpi
underwent the same procedure. Thus, data collected from phase 1 and phase 2 carpi was used for analyses until two months. Therefore, number
of radio-carpal (RC)-joints assessed for synovial parameters were n = 36 until two months (8 RC-joints control, 14 RC-joints MSC-naïve, 14 RC-joints
MSC-primed), and n = 18 for six months (4 RC-joints control, 7 RC-joints MSC-naïve, 7 RC-joints MSC-primed). Light grey lines and symbols
represent control group, dark grey lines and symbols represent MSC-naïve group and black lines and symbols represent MSC-primed group.
Results are presented as Mean ± SEM of each parameter at the evaluated time-points. Significant differences are shown between time-points
within each group: time-points from Time 0 (pre-lesion) to Week 5 (just before second injection) were compared to the time of the first injection
(Week 2). Subsequent time-points were compared to second injection (Week 5). a Evolution of the SF total protein (g/dl). b Evolution of the
haptoglobin concentration (mg/ml) in SF and serum along the study. Continuous lines represent SF values and discontinuous lines represent
serum values (control, n = 4 animals; MSC-naïve, n = 7 animals; MSC-primed, n = 7 animals). Asterisks (*) are used for significant differences in SF
and hashes (#) are used for significant differences in serum. c Evolution of the SF total white cells count (cells/μL) along the study. d Evolution of
the percentage (%) of neutrophils in SF along the study. (* = p < 0.05, ** = p < 0.01, *** = p < 0.001; # = p < 0.05, ## = p < 0.01, ### = p < 0.001)
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compared to RC-joints where MSC-primed were injected
at two months (p < 0.05) and both MSC-treatments re-
duced subchondral bone damage compared to control
(non-significant) (Table 2, Fig. 3c).
Macroscopic and histopathological assessments
Overall, macroscopic observation of the articular sur-
faces revealed lesions in the cartilage, from discoloration
and fibrillation to erosions of different extent, which
were suggestive of degenerative changes led by the in-
flammation induced. Gross anatomy scores were similar
between the three groups at six months (phase 1
RC-joints), but lower at two months (phase 2 RC-joints)
in both MSC-treated groups compared to control
(MSC-naïve, p < 0.05; MSC-primed, non-significant).
Within each group, both MSC-treated groups showed
significantly lower scores at two months of progression
compared to six months (p < 0.05), whereas the control
group showed similar scores at both end-points (Fig. 4).
On the whole, histopathology revealed findings related
to damaged cartilage such as fibrillation and chondrocyte
loss, and signs of synovium inflammation like cellular in-
filtration or subintimal changes. Overall score did not re-
veal differences between phase 1 and 2 within each group
neither for cartilage nor for synovium. Comparison be-
tween groups at each phase neither showed significant dif-
ferences in cartilage histopathology (Fig. 5a.1, b.1), nor in
SOFG histochemistry, but control group showed signifi-
cantly higher score (p < 0.05) at six months compared to
two months, meaning reduced proteoglycan content at
long-term, while neither MSC-naïve nor MSC-primed
groups showed significant differences between phase 1
and 2 (Fig. 5a.2, b.2). On the other hand, synovium evalu-
ation showed significantly lower total score in
MSC-primed (p < 0.01) and MSC-naïve groups (p < 0.01),
compared to control, at two (phase 2) and six months
(phase 1), respectively (Fig. 5a.3, b.3). Analyzing each indi-
vidual parameter, MSC-primed group showed lower
scores at two months for vascularity (p < 0.05) and subin-
timal fibrosis (p < 0.01); whereas MSC-naïve group pro-
vided lower score at six months for cellular infiltration
(p < 0.05), subintimal edema (p < 0.01) and subintimal
fibrosis (p < 0.01) (Additional file 7).
Table 1 Radiology scores (Mean ± SD) for each group (control,
MSC-naïve, MSC-primed) at each assessed time-point
Time Control MSC-naïve MSC-primed
Week 0 (pre-lesion) 0.00 ± 0.00a
n = 8
0.00 ± 0.00a
n = 14
0.00 ± 0.00a
n = 14
Week 2 (first injection) 2.50 ± 1.31b
n = 8
1.93 ± 0.99b
n = 14
1.43 ± 0.85b
n = 14
2 months 3.00 ± 0.93b
n = 8
3.43 ± 1.82b
n = 14
2.71 ± 1.33b
n = 14
4 months 2.50 ± 0.58b
n = 4
3.86 ± 1.77b
n = 7
2.71 ± 1.70b
n = 7
6 months 2.50 ± 1.00b
C4
4.43 ± 1.90b
n = 7
3.00 ± 1.29b
n = 7
The number (n) of radio-carpal joints assessed is showed for each time-point
within each group. Higher scores mean higher severity of the radiologic
findings, 6 being the highest possible score. Different letters mean statistically
significant differences (p < 0.05). Note that significant differences were only
found between pre-lesion and subsequent evaluations within each group, but
not between groups at any time
Fig. 3 Representative images of the radiology, ultrasonography and
magnetic resonance imaging (MRI) assessments, taken from one
animal from each group (control, MSC-naïve and MSC-primed). a
Radiologic images (frontal views) are presented for two (score 3)
and six months (score 3–4) of progression. Score 6 is the highest
possible. Joint space narrowing and marginal bone remodeling
(white arrows) were progressively observed; note that the radiologic
evolution was similar between the three groups. b Ultrasound
images are presented for Week 2 (first injection) and Week 3. Note
that synovial effusion (dashed line) was faster reduced in both MSC-
naïve and MSC-primed groups than in control. c Magnetic
resonance images (T2* gradient echo [GE], sagittal planes) are
presented for showing the different synovial effusion (black arrows)
found between groups at two months (scores 1, 0 and 3 were
assigned to the images showed for control, MSC-naïve and MSC-
primed groups, respectively)
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Gene expression analysis
Cartilage
Cartilage from RC-joints from phase 2 (two months pro-
gression) of the MSC-primed group showed significant
upregulation of collagen type II (COL2A1), inducible
nitric oxide synthase (iNOS) and transforming growth
factor (TGF)-β1 (p < 0.05) and downregulation of cyclo-
oxygenase (COX)-2, interleukin (IL)-1β (p < 0.05) and
TNFα (non-significant) compared to the control group.
Additionally, MSC-primed group upregulated MMP-3
Table 2 Magnetic resonance imaging (MRI) scores (Mean ± SD) for each group (control, MSC-naïve, MSC-primed)
MRI grading parameter Two months end-point
(Phase 2 carpi)
Six months end-point
(Phase 1 carpi)
Control
n = 4
MSC-naïve
n = 7
MSC-primed
n = 7
Control
n = 4
MSC-naïve
n = 7
MSC-primed
n = 7
Osteophyte formation 0.25 ± 0.50 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.33 ± 0.58 0.00 ± 0.00
Synovial effusion 1.50 ± 0.58a,b 0.67 ± 0.58a,c 2.25 ± 0.50b 1.25 ± 0.50 1.33 ± 0.58 1.75 ± 0.96
Osseous edema 0.25 ± 0.50 0.33 ± 0.58 1.25 ± 1.26 0.00 ± 0.00 0.00 ± 0.00 0.25 ± 0.50
Subchondral bone damage 1.00 ± 0.00 0.33 ± 0.58 0.50 ± 0.58 0.25 ± 0.50 0.33 ± 0.58 0.75 ± 0.50
Scores are shown for each MRI grading parameter in each group at each assessed end-point (six and two months, phases 1 and 2). The number (n) of radio-carpal
(RC) joints assessed in each group at each end-point is showed in the table. Higher scores mean higher severity of the MRI findings, 4 being the highest possible
score for each parameter. Different letters mean statistically significant differences (p < 0.05). Note that significant differences were only found between groups for
the parameter synovial effusion at two months (phase 2), but not for other parameters or between two and six months
Fig. 4 Gross anatomy outcome was assessed by visual examination of joint surfaces. a Representative images of the macroscopic appearance of
the articular cartilage surface in one animal from each group (control, MSC-naïve, MSC-primed) at both end-points (two and six months). Assigned
scores in these images were 3 (control, both 2 and 6 months), 0 (MSC-naïve, 2 months), 1 (MSC-naïve, 6 months; MSC-primed, 2 months) and 2 (MSC
primed, 6 months). b Mean ± SEM of the gross anatomy score for each group at two months end-point (phase 2 lesion, light grey bars; control, n = 4
radio-carpal [RC]-joints; MSC-naïve, n = 7 RC-joints; MSC-primed, n = 7 RC-joints) and at six months end-point (phase 1 lesion, dark grey bars; control,
n = 4 RC-joints; MSC-naïve, n = 7 RC-joints; MSC-primed, n = 7 RC-joints). The highest possible score is 4. (* = p < 0.05)
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expression compared to MSC-naïve (Fig. 6a.1). At six
months (RC-joints from phase 1), cartilage from both
MSC-treated groups significantly upregulated collagen type
I (COL1A1) (p < 0.05 MSC-naïve; p < 0.01 MSC-primed)
and downregulated TNFα (p < 0.05) compared to the con-
trol. In addition, MSC-primed group showed significantly
higher expression of COL2A1, aggrecan (ACAN), cartilage
oligomeric matrix protein (COMP), MMP-3, tissue inhibi-
tor of metalloproteinases (TIMP)-2 and TGF-β1 (p < 0.05)
than control, and significant upregulation of iNOS
(p < 0.01) compared to MSC-naïve (Fig. 6a.2). Comparison
of cartilage gene expression between two and six months
within each group did not show significant differences in
the control group (data not shown). On the other hand, gene
expression at six months compared to two months was sig-
nificantly higher for MMP-13, TIMP-2 and COX2 (p < 0.05)
in both MSC-treated groups; MSC-naïve group significantly
downregulated TNFα (p < 0.05) and MSC-primed group
showed higher expression of ACAN, MMP-3, IL-1β and
TGF-β1 (p < 0.05) (Fig. 6b.1 and b.2).
Fig. 5 Histopathology and histochemical assessment of cartilage and synovium was performed assigning scores to several parameters. a
Representative histologic images from one animal of each group (control, MSC-naïve, MSC-primed) at both end-points (two and six months);
(A.1) Cartilage (hematoxylin-eosin [H&E], × 20): different degrees of fissuring/fibrillation of the cartilage surface, chondrocyte necrosis and areas of
focal cell loss can be observed, with more severe abnormalities for control animal at six months. Overall scores assigned to each image are as
follows: score 6 (control, 2 months), score 8 (control, 6 months; MSC-naïve, 2 and 6 months; MSC-primed, 2 months), score 7 (MSC-primed,
6 months); (A.2) Cartilage histochemistry (safranin O-fast green [SOFG], × 20): different degrees of SOFG stain uptake related to proteoglycan
content. Scores assigned to each image are as follows: score 4 (control, 6 months), score 3 (control, 2 months; MSC-naïve, 2 and 6 months; MSC-
primed, 6 months), score 2 (MSC-primed, 2 months); (A.3) Synovium (H&E, × 100): different degrees of mononuclear cells infiltration and changes in
vascularity can be observed, more markedly in the control group at both end-points. Overall scores assigned to each representative image are as
follows: score 16 (control, 2 months), score 14 (control, 6 months; MSC-naïve, 2 months), score 4 (MSC-naïve, 6 months), score 12 (MSC-primed,
2 months), score 10 (MSC-primed, 6 months). b Mean ± SEM of the scores assigned to each group at two months (phase 2, light grey bars; control, n
= 4 radio-carpal [RC]-joints; MSC-naïve, n = 7 RC-joints; MSC-primed, n = 7 RC-joints) and at six months (phase 1, dark grey bars; control, n = 4 RC-joints;
MSC-naïve, n = 7 RC-joints; MSC-primed, n = 7 RC-joints); (B.1) in cartilage histopathology (H&E, total histopathologic score [sum of scores from each
parameter], highest possible score is 12); (B.2) in cartilage histochemistry (SOFG, highest possible score is 4) and (B.3) in synovium histopathology
(H&E, total histopathologic score [sum of scores from each parameter], highest possible score is 20) (* = p < 0.05; ** = p < 0.01)
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Fig. 6 (See legend on next page.)
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Synovium
In synovium from RC-joints from phase 2 (two months
progression), MMP-3 expression was significantly lower
in MSC-naïve group (p < 0.05) than in MSC-primed,
MMP-13 was significantly downregulated in both
MSC-treated groups (p < 0.01) compared to control; and
TIMP-2, TNFα (p < 0.05) and IL-1β (p < 0.01) were sig-
nificantly downregulated in MSC-primed group com-
pared to control (Fig. 6c.1). At six months (RC-joints
from phase 1), significant MMP-3 upregulation and
MMP-13 downregulation (p < 0.05) over control was
found in MSC-primed group, and MSC-naïve treatment
significantly upregulated TIMP-2 (p < 0.01) and TNFα
(control, p < 0.05; MSC-primed, p < 0.01) compared to
the other groups (Fig. 6c.2). When comparing synovium
gene expression between two and six months within
each group, differences were not found in control
group (data not shown). Both MSC-treated groups
showed significantly lower expression of MMP-3 at two
than at six months (p < 0.05). In addition, significant
upregulation of MMP-13, TIMP-2 and TNFα (p < 0.05)
was found at six compared to two months in the
MSC-naïve group (Fig. 6d.1 and d.2).
Discussion
This study reports beneficial effects of repeated IA admin-
istration of allogeneic MSCs, both unstimulated and
primed with proinflammatory cytokines, in an equine
model of chemically induced-OA. Despite the lack of huge
differences between the two types of MSC-treatments, the
overall outcome suggested increased anti-inflammatory
and regulatory abilities of MSC-primed. Beneficial effects
were mainly found at limiting inflammation and subse-
quent cartilage degradation in an early stage. While
long-term benefit of cellular therapies is desired, previous
studies also showed that MSCs can improve the early
healing response, but are limited for enhancing the
long-term outcome [33, 35, 46]. This might be associated
to MHC expression induction by proinflammatory
cytokines [17], potentially leading to higher MSC-primed
immunogenicity that at first could be dampened by their
increased immunosuppressive properties but might com-
promise their long-term survival and effectivity [23].
To assess whether MSC-treatments may achieve dif-
ferent outcomes depending on the progression, and pro-
vided that previous studies found short-term benefit that
was not maintained in the longer-term, the study was
designed to enable two end-points evaluation. This
two-phase study design aimed at reducing the number
of animals by using both RC-joints of each one instead
of duplicating animals. It is quite common to use both
opposite joints in large animal models [34, 36], but some
considerations should be taken into account. To begin
with, as MSCs elicit paracrine signaling, it cannot be
completely discarded remote influence in contralateral
joints, even though MSC migration from one joint to
another appears to be unlikely [31, 32]. Secondly, arth-
ritis induction led to transient altered weight-bearing of
the contralateral forelimb, but clinical affectation of the
contralateral RC-joints was not detected in any case be-
cause of this transient overloading.
Although amphotericin-B model does not mimic the
most common pathogenesis of OA (i.e. post-traumatic), it
is acknowledged that inflammation plays a major role in
initiation and progression of cartilage damage. Further-
more, this study mainly aimed at assessing regulatory abil-
ities of MSCs in limiting inflammation and subsequent
cartilage erosive lesions, thus relevant inflammatory com-
ponent playing an important role. Even though results ob-
tained using this model may not be directly extrapolated
into naturally-occurring OA, the inflammatory regulation
and the delay in cartilage degradation observed are of sig-
nificance and can contribute to further clarify the role
exerted by MSCs in OA.
The IA injection of amphotericin-B resulted in an arth-
ritis model accordingly to previous reports [11, 47]. Previ-
ous studies in the horse using MSCs in experimental
models showed no clinical differences between treated
(See figure on previous page.)
Fig. 6 Gene expression related to extracellular matrix production, destruction/remodeling and joint inflammation in cartilage and synovium.
Results are shown as Mean ± SEM of the relative mRNA expression. a Gene expression in cartilage compared between all the three groups (A.1)
at two months end-point (phase 2 lesion; control, n = 4 radio-carpal [RC]-joints; MSC-naïve, n = 7 RC-joints; MSC-primed, n = 7 RC-joints) and (A.2)
at six months end-point (phase 1 lesion; control, n = 4 RC-joints; MSC-naïve, n = 7 RC-joints; MSC-primed, n = 7 RC-joints). b Gene expression in
cartilage compared between two and six months (B.1) for MSC-naïve group (n = 7 animals; n = 7 RC-joints for two months and n = 7 RC-joints for
six months) and (B.2) for MSC-primed group (n = 7 animals; n = 7 RC-joints for two months and n = 7 RC-joints for six months). c Gene expression
in synovium compared between all the three groups (C.1) at two months end-point (phase 2 lesion; control, n = 4 RC-joints; MSC-naïve, n = 7 RC-
joints; MSC-primed, n = 7 RC-joints) and (C.2) at six months end-point (phase 1 lesion; control, n = 4 RC-joints; MSC-naïve, n = 7 RC-joints; MSC-
primed, n = 7 RC-joints). d Gene expression in synovium compared between two and six months (D.1) for MSC-naïve group (n = 7 animals; n = 7
RC-joints for two months and n = 7 RC-joints for six months) and (D.2) for MSC-primed group (n = 7 animals; n = 7 RC-joints for two months and
n = 7 RC-joints for six months). Note that the Y axe of some graphs has been divided into two or three segments for clearer representation of
smaller bars. COL1A1, collagen type I; COL2A1, collagen type II; ACAN, aggrecan; COMP, cartilage oligomeric matrix protein; MMP-3, matrix
metalloproteinase 3; MMP-13, matrix metalloproteinase 13; TIMP-2, tissue inhibitor of metalloproteinase 2; iNOS, inducible nitric oxide synthase;
COX-2, cyclooxygenase 2; TNFα, tumor necrosis factor alpha; IL-1β, interleukin 1 beta; TGF-β1, transforming growth factor beta 1
(* = p < 0.05, ** = p < 0.01)
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and control groups [19, 34], but other studies in
naturally-occurring joint pathologies showed enhanced
clinical outcome [28, 48]. In our study, differences in the
clinical progress between control and MSC-treated
groups were slight, but the evolution of clinical param-
eters suggested faster normalization in the MSC-treated
groups. Accordingly, synovial parameters were also
normalized faster in the MSC-treated RC-joints. In the
SF, the most remarkable effect of the MSC-treatments
was the significant reduction of the parameters earlier
than in the control. Reduction of TP has also been
reported by using autologous MSCs in the same model
[11] and in our study TP was quicker reduced in the
MSC-primed group. Haptoglobin has been recently
described in the horse as a potential SF inflammatory
marker in a study using the same lesion model [38]. In
the present study, significant haptoglobin reduction in
SF was first reached by both MSC-treatments. Similarly,
MSC-treatments normalized the percentages of white
cells populations sooner than control, even if the tWCC
reduction was not significant as observed with autologous
MSCs [19].
Therefore, taking together both clinical and synovial
findings, it was noticed an anti-inflammatory effect elic-
ited by both MSC-treatments at first stage after adminis-
tration, especially after the first injection when joint
inflammation was higher. Repeated administration of
allogeneic MSC-naïve was well tolerated, accordingly to
that reported in healthy joints [27]. However, second in-
jection of allogeneic MSC-primed led to a slight transi-
ent inflammatory reaction, indicating that these cells
might have increased immunogenicity as discussed
above [17]. Interestingly, only second injection of these
cells but not the first one produced this effect. This
might have been due to the generation of immune mem-
ory, as it was recently reported in the horse the produc-
tion of functional antibodies against MHC-mismatched
MSCs [49]. One limitation of our study was that
MHC-matching was not assessed between donors and
receptors and authors hypothesize that alloantibodies pro-
duction might have been implied, but the results of our
study do not allow confirmation of this hypothesis. Never-
theless, this inflammatory reaction was transient and
spontaneously resolved, but raises questions about the
survival and immune allorecognition of MSC-primed re-
quiring further investigation.
Regarding imaging assessment, ultrasonography sug-
gested quicker reduction of the joint effusion shortly after
first injection of both MSC-treatments, in agreement with
clinical and synovial parameters. On the other hand,
higher synovial effusion later noticed by MRI in
MSC-primed group at two months would concord with
the mild reaction observed after second injection of
MSC-primed, but not for MSC-naïve, as discussed above.
Beyond these observations, radiology and MRI were un-
able to reveal obvious differences between groups. Simi-
larly, in a sheep model it was not observed radiologic
changes but ultrasonography was useful for revealing joint
alterations [33], and radiology and MRI did not provide
different outcomes between control and MSC-treated
joints in previous equine studies [34].
Improved cartilage macroscopic appearance was ob-
served in both MSC-treated groups, which was more ob-
vious at short-term thus suggesting a delaying effect on
the progression of cartilage degradative changes. Accord-
ingly, a previous study using the same lesion model
showed enhanced macroscopic appearance after autolo-
gous MSC administration, but did not report differences
between two and six months of progression [11]. On the
other hand, cartilage histopathology did not show signifi-
cant improvement in MSC-treated groups. Whereas gross
appearance is overall assessed, histopathology evaluation
is carried out on specific sites, which might explain the
differential results observed between gross and histopath-
ology scores. Previous studies using different equine OA
models neither provided remarkable improvement after
autologous MSC administration in the histopathology of
cartilage and synovium [19, 35]. However, in this study
synovium histopathology did reveal significantly improved
score at two months (phase 2) for MSC-primed and at six
months (phase 1) for MSC-naïve. These findings might
suggest anti-inflammatory potential earlier elicited by
MSC-primed that might not be reached by MSC-naïve
until longer-term. As SOFG stains proteoglycans in the
cartilage ECM, higher stain uptake reflects better quality
of the repaired tissue [43]. Despite no statistical differ-
ences between control and treated groups, control group
showed significantly higher loss of proteoglycans at six
than at two months. However, MSC-treated groups did
not show this significantly worsening evolution, thus sug-
gesting that progression of cartilage degradation might
have been delayed by both treatments, accordingly to that
suggested by the macroscopic appearance. Moreover, even
though not significant differences were found between
groups, MSC-primed showed higher proteoglycan content
at two months. Overall, histologic exam showed enhanced
effects of MSC-primed at short-term which were not ap-
parently maintained at longer-term. This observation
might be also related with faster elimination of these cells,
potentially related to the immunogenicity issues afore-
mentioned [23].
Despite similar histological cartilage outcome between
groups, the upregulation of COL2A1, ACAN and COMP
in MSC-primed group in the phase 1 (six months) sug-
gested an attempt of cartilage reparation with better
quality of the healing tissue, as these genes are related
with cartilage ECM production and they are downregu-
lated during OA [50]. Similarly, increased collagen type
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II in MSC-treated joints has been reported in a rat
model [51] and MSCs provided higher aggrecan content
in an equine model [34]. Upregulation of COL1A1 in
both MSC-treated groups might be also indicating an at-
tempt of the chondrocytes to initiate repairs even if
COL1A1 is related to fibroblastic rather than to chon-
drocytic phenotype [52].
Changes in MMPs and TIMP expression after both
MSC-treatments were mainly found in the synovium, ac-
cording to previous report of this structure as a major target
of MSC therapy for modulating degrading enzymes [53].
Both MSC-treatments reduced MMP-13 expression in
synovium at two months end-point (phase 2), whereas only
MSC-primed also showed MMP-13 downregulation at six
months (phase 1). Accordingly, MMP-13 expression is re-
duced in synovium explants cultured in the supernatant of
MSCs primed with TNFα and IFNγ [54]. On the other
hand, even if MMP-3 is a degradative enzyme, a protective
role of the cartilage has also been proposed [55, 56], so its
upregulation in both synovium and cartilage from
MSC-primed group might be related to an attempt of re-
storing the functional balance in the joint. Furthermore, the
MMP inhibitor TIMP-2 was found upregulated in cartilage
from MSC-primed group at six months and its expression
tended to change towards the same direction than MMP-13
in the synovium of this group, maybe aiming at reversing
the imbalance between them present during OA [57].
Although nitric oxide (NO) is considered an OA
pro-inflammatory marker, protective roles in the joint
[58] and immunomodulatory properties have also been
attributed to NO [59]. Thus, the role of iNOS upregula-
tion in cartilage from MSC-primed group might not be
detrimental but regulatory [60]. Expression of iNOS by
chondrocytes is mainly induced by IL-1 and TNFα,
which are the major pro-inflammatory cytokines in-
volved in OA and they are in vitro upregulated in equine
chondrocytes after inflammatory stimuli [61] and in vivo
in cartilage from equine OA carpi [62]. Expression of
TNFα was reduced in the cartilage of both MSC-treated
groups at six months, similarly to that previously re-
ported in vitro [54]. However, only MSC-primed also
downregulated TNFα at two months in both the cartilage,
even though not significantly, and the synovium. Further-
more, whereas MSC-naïve did not significantly change the
expression of IL-1β over control in any case, MSC-primed
significantly downregulated IL-1β at two months in cartil-
age and at six months in synovium. Therefore, higher
anti-inflammatory effect of MSC-primed on joint tissues
was suggested. The different end-points at which each
change was found to be significant may have been due to
different cytokine dynamics during OA [63]. TNFα and
IL-1β are able to induce the secretion of PGE2, synthesized
by COX2, which increased concentrations and gene expres-
sion are related with decreased proteoglycans synthesis and
increased ECM destruction during OA [14, 64, 65]. PGE2
decreased in equine cartilage explants exposed to
MSC-primed conditioned media [54] and in SF from OA
experimental horses treated with autologous MSCs
[19].We observed lower expression of COX2 at two than at
six months in cartilage from both MSC-treated groups, but
only MSC-primed significantly downregulated COX2 com-
pared to control. This finding might be related with higher
proteoglycan content, as shown by SOFG cartilage staining,
in the MSC-primed group at two months compared to the
other conditions. TGF-β1 is considered to have a cartilage
protective role through stimulating ECM components syn-
thesis and by reducing MMP expression [66], as well as
regulating the joint inflammation [67]. Thus, the upregula-
tion of TGF-β1 in cartilage after MSC-primed at both
end-points suggested enhanced repair stimulation and car-
tilage protection [66]. This growth factor predominates
during the remission phase of the OA [63], which might ex-
plain the higher expression observed at six months.
Conclusions
Overall, MSC-primed treatment suggested more powerful
anti-inflammatory and regulatory effects, but the slight in-
flammatory reaction observed after their second injection
requires further investigation about immunogenicity impli-
cations. Beneficial effects were mostly observed at
short-term, which might be due to MSC short-term life
after in vivo administration, especially for the allogeneic
MHC-mismatched ones. Nevertheless, our results suggest
an in vivo enhanced regulatory ability of MSC-primed for
limiting inflammation and subsequent cartilage degradation
in this model of joint pathology. While further investigation
is warranted to clarify the immunogenic implications of
using allogeneic MSC-primed and the extent to which
these results can be extrapolated, findings of this study con-
tribute to better understand the mechanisms underlying
the beneficial effects of MSCs in joint pathology and how
MSC therapeutic potential could be influenced.
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